Disclosed positions
| ABIVAX SA | ABVX | SPONSORED ADS | $240,494,722 | 1,804,703 | SH | None |
| PROTAGONIST THERAPEUTICS INC | PTGX | COM | $117,782,587 | 960,863 | SH | None |
| ROIVANT SCIENCES LTD | ROIV | SHS | $111,726,513 | 3,157,008 | SH | None |
| STATE STR SPDR S&P 500 ETF T | SPY | TR UNIT | $96,398,299 | 129,087 | SH | None |
| IMMUNOVANT INC | IMVT | COM | $89,802,487 | 2,330,716 | SH | None |
| ZAI LAB LTD | ZLAB | ADR | $64,011,646 | 3,369,034 | SH | None |
| AGIOS PHARMACEUTICALS INC | AGIO | COM | $47,799,647 | 1,288,053 | SH | None |
| CRINETICS PHARMACEUTICALS IN | CRNX | COM | $45,730,234 | 1,222,080 | SH | None |
| EA SERIES TRUST | BOXX | ALPHA ARCH 1-3 | $39,473,966 | 337,125 | SH | None |
| CYTOKINETICS INC | CYTK | COM NEW | $39,009,097 | 457,907 | SH | None |
| SEPTERNA INC | SEPN | COM | $31,505,617 | 940,747 | SH | None |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | COM | $30,979,196 | 3,145,096 | SH | None |
| EDITAS MEDICINE INC | EDIT | COM | $28,800,360 | 8,889,000 | SH | None |
| DENALI THERAPEUTICS INC | DNLI | COM | $26,467,938 | 1,029,080 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $25,211,922 | 283,982 | SH | None |
| VIR BIOTECHNOLOGY INC | VIR | COM | $25,033,539 | 2,456,677 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $24,859,162 | 74,253 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $24,364,802 | 228,520 | SH | None |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $23,053,158 | 619,542 | SH | None |
| VIKING THERAPEUTICS INC | VKTX | COM | $22,393,222 | 574,038 | SH | None |
| TAYSHA GENE THERAPIES INC | TSHA | COM SHS | $20,705,573 | 3,040,466 | SH | None |
| MONOPAR THERAPEUTICS INC | MNPR | COM NEW | $20,147,121 | 217,595 | SH | None |
| OVID THERAPEUTICS INC | OVID | COM | $19,953,019 | 7,417,479 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $19,676,689 | 387,718 | SH | None |
| ENANTA PHARMACEUTICALS INC | ENTA | COM | $19,602,956 | 1,344,510 | SH | None |
| ISHARES TR | IWM | RUSSELL 2000 ETF | $18,778,125 | 62,500 | SH | Put |
| STATE STR SPDR S&P 500 ETF T | SPY | TR UNIT | $18,669,250 | 25,000 | SH | Put |
| NEKTAR THERAPEUTICS | NKTR | COM NEW | $17,046,485 | 244,184 | SH | None |
| INSPIRE MED SYS INC | INSP | COM | $16,711,664 | 374,617 | SH | None |
| REVOLUTION MEDICINES INC | RVMD | COM | $16,388,686 | 87,509 | SH | None |
| ESTABLISHMENT LABS HLDGS INC | ESTA | COM | $15,927,966 | 185,619 | SH | None |
| PROTHENA CORP PLC | PRTA | SHS | $15,218,898 | 1,554,535 | SH | None |
| RHYTHM PHARMACEUTICALS INC | RYTM | COM | $15,117,623 | 136,158 | SH | None |
| INHIBIKASE THERAPEUTICS INC | IKT | COM NEW | $14,996,026 | 7,387,205 | SH | None |
| UNIQURE NV | QURE | SHS | $14,954,392 | 324,672 | SH | None |
| RALLYBIO CORP | RLYB | COM | $14,821,632 | 926,352 | SH | None |
| REGENERON PHARMACEUTICALS | REGN | COM | $13,847,576 | 22,208 | SH | None |
| INVENTIVA SA | IVA | ADS | $13,633,160 | 3,606,656 | SH | None |
| SUTRO BIOPHARMA INC | STRO | COM SHS | $13,413,265 | 404,014 | SH | None |
| IONIS PHARMACEUTICALS INC | IONS | COM | $13,184,817 | 166,286 | SH | None |
| BRIDGEBIO PHARMA INC | BBIO | COM | $13,159,797 | 176,689 | SH | None |
| SAREPTA THERAPEUTICS INC | SRPT | COM | $13,129,763 | 730,649 | SH | None |
| CYTOMX THERAPEUTICS INC. | CTMX | COM | $12,619,193 | 3,365,118 | SH | None |
| VOR BIOPHARMA INC | VOR | COM NEW | $12,530,325 | 680,626 | SH | None |
| SPDR SERIES TRUST | BIL | ST STR BLO 1 ETF | $12,425,009 | 135,585 | SH | None |
| EQUILLIUM INC | EQ | COM | $12,027,421 | 3,758,569 | SH | None |
| ADLAI NORTYE LTD | ANL | SPONSORED ADS | $11,704,758 | 1,017,805 | SH | None |
| CLIMB BIO INC | CLYM | COM | $10,727,343 | 822,649 | SH | None |
| SPDR SERIES TRUST | XBI | ST STR SP BIOT | $10,666,050 | 67,400 | SH | Put |
| HELIX ACQUISITION CORP III | HLXC | USD CL A ORD SHS | $10,600,000 | 1,000,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 22 positions lack a resolved ticker and 10 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.